ChromaCode
Molecular diagnostics company whose HDPCR™ technology enhances multiplexing capabilities on existing PCR hardware, enabling more targets per test without new equipment investment.
Website
https://www.chromacode.comLocation
Carlsbad, California, USA
Founded
2015
Investors
1
Categories
molecular-diagnostics, pcr, multiplexing, diagnostics, biotech
Notes
ChromaCode is a molecular diagnostics company that has developed High Definition PCR (HDPCR™) technology, which dramatically enhances the multiplexing capabilities of existing PCR instruments. This technology allows laboratories to run more complex, multi-target tests on their current equipment without requiring new hardware investment.
The company's technology is particularly valuable for infectious disease testing, where the ability to test for multiple pathogens simultaneously can improve diagnostic accuracy and efficiency.
Team
- Jason Myers - Chief Executive Officer
- LinkedIn: linkedin.com/in/jasonmyers
- David Crothers - Chief Technology Officer
Additional Research Findings
- HDPCR™ (High Definition PCR) technology
- Enhances multiplexing on existing PCR platforms
- Eliminates need for new equipment investment
- Focus on infectious disease testing
- Headquarters in Carlsbad, California
- Enables higher-plex testing on standard instruments
- Compatible with major PCR platform manufacturers
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |